<p>Dominari（纳斯达克股票代码：DOMH - 获取免费报告）预计将在 5 月 13 日（星期三）发布其财报。分析师预计该公司将宣布每股收益为（$0.17），季度收入为 3007.60 万美元。</p>
<h2>Dominari 股价上涨 7.6%</h2>
<p>DOMH 股票在星期三开盘价为 $3.39。该公司的 50 日移动平均价格为 $3.00，200 日移动平均价格为 $3.96。公司的市值为 7665 万美元，市盈率为 -0.87，贝塔值为 0.69。Dominari 的 12 个月低点为 $2.68，12 个月高点为 $8.40。</p>
<h2>Dominari 分红公告</h2>
<p>该公司最近还宣布了一项特别分红，将于 5 月 29 日（星期五）支付。5 月 15 日（星期五）登记的投资者将获得每股 $0.31 的分红。除息日期为 5 月 15 日（星期五）。</p>
<h2>机构投资者对 Dominari 的看法</h2>
<p>一些机构投资者和对冲基金最近买入和卖出了 DOMH 的股票。Geode Capital Management LLC 在第二季度将其在 Dominari 的持仓提高了 2.9%。Geode Capital Management LLC 现在拥有 66,283 股公司股票，价值 361,000 美元，此前在上个季度增持了 1,866 股。Jane Street Group LLC 在第二季度购买了 Dominari 的新股份，价值约 158,000 美元。Vanguard Group Inc. 在第三季度将其在 Dominari 的持股提高了 8.0%。Vanguard Group Inc. 现在拥有 345,896 股公司股票，价值 2,452,000 美元，此前在上个季度增持了 25,694 股。Two Sigma Investments LP 在第三季度购买了 Dominari 的新股份，价值约 771,000 美元。最后，Millennium Management LLC 在第三季度购买了 Dominari 的新股份，价值约 213,000 美元。42.48% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>分析师评级调整</h2>
<p>DOMH 曾受到多份分析师报告的关注。Weiss Ratings 在 1 月 12 日的研究报告中将 Dominari 的股票评级从 “持有（c-）” 下调至 “卖出（d+）”。Wall Street Zen 在 4 月 18 日的研究报告中将 Dominari 的股票评级从 “持有” 下调至 “卖出”。根据 MarketBeat 的数据，一位研究分析师对该股票给予了 “卖出” 评级，该公司的平均评级为 “卖出”。</p>
<p><strong>查看我们关于 Dominari 的最新报告</strong></p>
<h2>关于 Dominari</h2>
<p>（获取免费报告）</p>
<p>Dominari Holdings Inc 是一家生物技术公司，专注于开发小分子抗癌治疗药物。该公司的治疗药物管线包括前列腺癌、胰腺癌、急性髓性白血病（AML）和急性淋巴细胞白血病的治疗。它正在开发胰腺药物候选物 DHA-dFdC，以及用于急性髓性白血病和急性淋巴细胞白血病的小分子治疗 KPC34。该公司还在开发一种抗病毒平台，能够抑制包括流感病毒、埃博拉病毒和马尔堡病毒、SARS-CoV、MERS-CoV 和 SARS-CoV-2 在内的病毒的复制。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RE9NSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RE9NSA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 $1,000 在 Dominari 吗？</h2>
<p>在你考虑 Dominari 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Dominari 并不在名单上。</p>
<p>虽然 Dominari 目前在分析师中被评为 “卖出”，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

DOMH

动态生物技术与基因组 ETF - Invesco

纽交所高增长板生物技术指数 ETF - First Trust

2 倍做多纳斯达克生物技术 ETF - ProShares

标普生物技术 3 倍做多 - Direxion

纳斯达克生物科技指数 ETF - iShares Nasdaq

生物科技 ETF - VanEck Vectors

标普生物技术 ETF - SPDR

医药突破 ETF - ALPS

<p>Dominari (NASDAQ:DOMH) 将于 5 月 13 日发布季度财报，分析师预测每股亏损 0.17 美元，收入为 3008 万美元。该股上涨了 7.6%，开盘价为 3.39 美元。Dominari 还宣布每股特别股息 0.31 美元，将于 5 月 29 日支付。机构投资者持有该股 42.48%，近期有 Geode Capital 和 Vanguard 等公司的活动。分析师已将该股评级下调至 “卖出”，反映出对其表现的谨慎展望</p>

<p>Dominari (NASDAQ:DOMH - Get Free Report) is expected to issue its resultson Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $30.0760 million for the quarter.</p>
<div class="lb-trans"><p>Dominari（纳斯达克股票代码：DOMH - 获取免费报告）预计将在 5 月 13 日（星期三）发布其财报。分析师预计该公司将宣布每股收益为（$0.17），季度收入为 3007.60 万美元。</p>
</div><h2>Dominari Trading Up 7.6%</h2>
<div class="lb-trans"><h2>Dominari 股价上涨 7.6%</h2>
</div><p>Shares of DOMH stock opened at $3.39 on Wednesday. The firm has a fifty day moving average price of $3.00 and a 200 day moving average price of $3.96. The company has a market cap of $76.65 million, a P/E ratio of -0.87 and a beta of 0.69. Dominari has a 12 month low of $2.68 and a 12 month high of $8.40.</p>
<div class="lb-trans"><p>DOMH 股票在星期三开盘价为 $3.39。该公司的 50 日移动平均价格为 $3.00，200 日移动平均价格为 $3.96。公司的市值为 7665 万美元，市盈率为 -0.87，贝塔值为 0.69。Dominari 的 12 个月低点为 $2.68，12 个月高点为 $8.40。</p>
</div><h2>Dominari Dividend Announcement</h2>
<div class="lb-trans"><h2>Dominari 分红公告</h2>
</div><p>The company also recently announced a special dividend, which will be paid on Friday, May 29th. Investors of record on Friday, May 15th will be paid a dividend of $0.31 per share. The ex-dividend date is Friday, May 15th.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项特别分红，将于 5 月 29 日（星期五）支付。5 月 15 日（星期五）登记的投资者将获得每股 $0.31 的分红。除息日期为 5 月 15 日（星期五）。</p>
</div><h2>Institutional Investors Weigh In On Dominari</h2>
<div class="lb-trans"><h2>机构投资者对 Dominari 的看法</h2>
</div><p>A number of institutional investors and hedge funds have recently bought and sold shares of DOMH. Geode Capital Management LLC lifted its position in Dominari by 2.9% in the second quarter. Geode Capital Management LLC now owns 66,283 shares of the company's stock valued at $361,000 after acquiring an additional 1,866 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of Dominari in the second quarter valued at about $158,000. Vanguard Group Inc. raised its holdings in shares of Dominari by 8.0% in the third quarter. Vanguard Group Inc. now owns 345,896 shares of the company's stock valued at $2,452,000 after buying an additional 25,694 shares during the last quarter. Two Sigma Investments LP purchased a new stake in shares of Dominari in the third quarter valued at about $771,000. Finally, Millennium Management LLC purchased a new stake in shares of Dominari in the third quarter valued at about $213,000. 42.48% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>一些机构投资者和对冲基金最近买入和卖出了 DOMH 的股票。Geode Capital Management LLC 在第二季度将其在 Dominari 的持仓提高了 2.9%。Geode Capital Management LLC 现在拥有 66,283 股公司股票，价值 361,000 美元，此前在上个季度增持了 1,866 股。Jane Street Group LLC 在第二季度购买了 Dominari 的新股份，价值约 158,000 美元。Vanguard Group Inc. 在第三季度将其在 Dominari 的持股提高了 8.0%。Vanguard Group Inc. 现在拥有 345,896 股公司股票，价值 2,452,000 美元，此前在上个季度增持了 25,694 股。Two Sigma Investments LP 在第三季度购买了 Dominari 的新股份，价值约 771,000 美元。最后，Millennium Management LLC 在第三季度购买了 Dominari 的新股份，价值约 213,000 美元。42.48% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>DOMH has been the subject of a number of analyst reports. Weiss Ratings downgraded shares of Dominari from a &#34;hold (c-)&#34; rating to a &#34;sell (d+)&#34; rating in a research note on Monday, January 12th. Wall Street Zen downgraded shares of Dominari from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Saturday, April 18th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of &#34;Sell&#34;.</p>
<div class="lb-trans"><p>DOMH 曾受到多份分析师报告的关注。Weiss Ratings 在 1 月 12 日的研究报告中将 Dominari 的股票评级从 “持有（c-）” 下调至 “卖出（d+）”。Wall Street Zen 在 4 月 18 日的研究报告中将 Dominari 的股票评级从 “持有” 下调至 “卖出”。根据 MarketBeat 的数据，一位研究分析师对该股票给予了 “卖出” 评级，该公司的平均评级为 “卖出”。</p>
</div><p><strong>View Our Latest Report on Dominari</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Dominari 的最新报告</strong></p>
</div><h2>About Dominari</h2>
<div class="lb-trans"><h2>关于 Dominari</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2.</p>
<div class="lb-trans"><p>Dominari Holdings Inc 是一家生物技术公司，专注于开发小分子抗癌治疗药物。该公司的治疗药物管线包括前列腺癌、胰腺癌、急性髓性白血病（AML）和急性淋巴细胞白血病的治疗。它正在开发胰腺药物候选物 DHA-dFdC，以及用于急性髓性白血病和急性淋巴细胞白血病的小分子治疗 KPC34。该公司还在开发一种抗病毒平台，能够抑制包括流感病毒、埃博拉病毒和马尔堡病毒、SARS-CoV、MERS-CoV 和 SARS-CoV-2 在内的病毒的复制。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Dominari</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RE9NSA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=DOMH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Dominari Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Dominari 吗？</h2>
</div><p>Before you consider Dominari, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Dominari 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dominari wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Dominari 并不在名单上。</p>
</div><p>While Dominari currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Dominari 目前在分析师中被评为 “卖出”，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Dominari (DOMH) Projected to Post Quarterly Earnings on Wednesday

Market Beat

Dominari

Dominari (DOMH) 预计将在周三发布季度财报